Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,266.0
26.2 (0.81%)

 

  • STI Straits Times Index
    3,266.0
    26.2 (0.81%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,692.7
    3.9 (0.23%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    28,347.0
    446.2 (1.60%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,754.4
    72.0 (2.68%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    21,281.8
    381.2 (1.82%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,497.8
    108.7 (1.70%)
    Index delayed 10 minutes
  • KOR KOSPI
    2,210.9
    14.8 (0.67%)
    Index delayed 20 minutes
  • XAO XAO
    6,170.7
    22.1 (0.36%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 755.4M
  • Value: 853.4M
  • Rise: 168
  • Fall: 136
  • Unch: 538

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Thomson Medical0.080+0.002
RHT HealthTrust0.037-0.001
Renaissance United^0.001-0.001
ThaiBev0.820+0.005
Ezion0.043-0.001
Rex Intl0.090-
Genting Sing1.100+0.020
Spackman0.025-0.001
Mapletree Log Tr1.390-
Mirach Energy^0.137-0.001

World Indices

World Indices
Name Last Change
Nasdaq 7,472.4 +45.5
HSI 28,347.0 +446.2
HSCEI 11,149.0 +211.7
Jakarta 6,497.8 +108.7
Nikkei 225 21,281.8 +381.2
SSE Comp 2,754.4 +72.0
Shanghai A 2,884.5 +75.4
Shanghai B 286.2 +5.4
ShenZhen A 1,506.7 +53.9
ShenZhen B 937.7 +21.1
Taiwan W 10,145.3 +80.5
PSE Comp 0.0
KOSPI 2,210.9 +14.8

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

QT Vascular QT VASCULAR LTD.
Quotes 10 Minutes Delayed. Updated at 18 Feb 2019 17:04
Last (SGD): 0.008 Change: +0.001 High: 0.008 Remarks: -
Change (%): +14.29 Low: 0.007
Open 0.007 Yesterday's Close 0.007
Buy Price 0.007 Sell Price 0.008
Buy Volume ('000) 13,325.0 Sell Volume ('000) 7,268.5
Cumulative Volume ('000) 5,745.5 Cumulative Value 41,744
Click to show Stock Prices chart

Key Statistics

EPS (SGD) a -0.01653 Trailing EPS (SGD) e 0.01612 NAV (SGD) b 0.0136
PE a - Trailing PE f 0.496 Price / NAV b 0.5882
Dividend (SGD) d - Cash In Hand (SGD) g 0.0100 Issued & Paid-up Shares c 2,092,632,000
Dividend Yield (%) d - Price / Cash In Hand g 0.800 Treasury Shares h -
Beta - 75 Daysi 0.041 R-Squared - 75 Days(%)i 0.07 Market Cap (M) 16.741
Beta - 500 Daysi 0.723 R-Squared - 500 Days (%)i 0.69 Enterprise Value (M) -0.851
Piotroski F Score 2 Exchange Code 5I0 Par Value ( SGD ) n.a.
52 Weeks Volatility (%) 42.594 6-Month VWAP 0.009 Free Float (%) 92.5
Under CPF Investment Scheme (CPFIS) No
Sector & Industry Manufacturing - Biotechnology
Category Classification Medical & Biotechnology
Index Components FTSE ST Catalist Index
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 07 Jan 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand.
  9. Beta and R-Squared are calculated in relation to the market index (STI or KLCI) using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference QT Vascular SGX 16.741 - 0.496 0.5882 -
Industry Biotechnology SGX 1,987.162 8.093 7.413 0.6879 4.747
Medical & Biotechnology SGX 1,112.710 26.551 28.944 1.4352 1.728
Index FTSE ST Catalist Index SGX 83.464 - - 0.9063 1.781
Local Peer Lonza SGX 5,937.213 7.663 7.663 0.6889 4.766
Local Peer Suntar Eco-City^ SGX 7.531 - - 0.3854 -
Global Peer AMGEN INC NASDAQ 117,199.839 13.962 13.962 9.3760 2.836
Global Peer GILEAD SCIENCES INC NASDAQ 86,650.380 15.885 15.885 4.0239 3.373
Global Peer AMGEN-T HKEx 622,278.000 9.459 9.459 6.3584 4.187
Global Peer BIOGEN INC NASDAQ 65,478.525 14.778 14.778 5.0215 -
Global Peer CELGENE CORP NASDAQ 63,504.675 15.696 15.696 10.3076 -
Global Peer CSL ASX 84,722.574 37.970 34.777 12.2926 1.219
Global Peer VERTEX PHARMACEUTICAL NASDAQ 48,081.412 22.930 22.930 10.8408 -
Global Peer REGENERON PHARMACEUTICALS INC NASDAQ 46,330.318 18.954 18.954 5.2905 -
Global Peer ILLUMINA INC NASDAQ 44,073.540 53.358 53.358 11.7279 -
Global Peer ALEXION PHARMACEUTICAL INC NASDAQ 28,921.358 372.700 372.698 3.1555 -
Other Global Peers AGILENT TECHNOLOGIES INC (NYSE), INCYTE CORPORATION (NASDAQ), BIOMARIN PHARMACEUTICAL (NASDAQ), SEATTLE GENETICS INC (NASDAQ), SINO BIOPHARM (HKEx), EXACT SCIENCES CORP (NASDAQ), WUXI BIO (HKEx), SAREPTA THERAPEUTICS INC (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), BEIGENE-B (HKEx), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), LOXO ONCOLOGY INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), TILRAY INC (NASDAQ), MODERNA INC (NASDAQ), EXELIXIS INC (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), ALKERMES PLC (NASDAQ), ARRAY BIOPHARMA INC (NASDAQ), FIBROGEN INC (NASDAQ), 3SBIO (HKEx), ALLOGENE THERAPEUTICS INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), GENSCRIPT BIO (HKEx), EMERGENT BIOSOLUTIONS INC (NYSE), BLUEPRINT MEDICINES CORP (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), GENOMIC HEALTH INC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), IMMUNOMEDICS INC (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), REPLIGEN CORP (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), ACCELERON PHARMA (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), INSMED INC (NASDAQ), XENCOR INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), SPARK THERAPEUTICS INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), ANAPTYSBIO INC (NASDAQ), REGENXBIO INC (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), OPKO HEALTH INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), MYOVANT SCIENCES LTD (NYSE), AIMMUNE THERAPEUTICS INC (NASDAQ), ALECTOR INC (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), UNIQURE N.V. (NASDAQ), VANDA PHARMACE INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), INTREXON CORP (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), ACCELERATE DIAGNOSTICS INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), AUDENTES THERAPEUTICS INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), MACROGENICS INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), NATERA INC (NASDAQ), EPIZYME INC (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), ASCLETIS-B (HKEx), ALDER BIOPHARMACEUTICALS INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), RETROPHIN INC (NASDAQ), HAOHAI BIOTEC (HKEx), INFLARX N V (NASDAQ), IMMUNOGEN INC (NASDAQ), RADIUS HEALTH INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), NOVAVAX INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), ARVINAS INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), VERACYTE INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), OMEROS CORP (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), SYNTHORX INC (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), AMAG PHARMACEUTICS INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), KURA ONCOLOGY INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), PROTHENA CORP PLC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), CKLIFE SCIENCES (HKEx), GLYCOMIMETICS INC (NASDAQ), LEE'S PHARM (HKEx), PDL BIOPHARMA INC (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), AGENUS INC (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), CYTOKINETICS INC (NASDAQ), TRANSLATE BIO INC (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), ESSEX BIO-TECH (HKEx), PROGENICS PHARMACEUTICALS INC (NASDAQ), MESOBLAST LTD (ASX), FIVE PRIME THERAPEUTICS (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), SINOVAC BIOTECH (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), INSYS THERAPEUTICS INC (NASDAQ), AVROBIO INC (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), ACHILLION PHARMACEUTICALS INC (NASDAQ), POLYNOVO LIMITED (ASX), DERMIRA INC (NASDAQ), MEDICINOVA INC (NASDAQ), ADURO BIOTECH INC (NASDAQ), XBIOTECH INC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), RTI SURGICAL INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), STARPHARMA HOLDINGS LIMITED (ASX), SOLID BIOSCIENCES INC (NASDAQ), NEUROINSIGHTS NEUROTECH (NASDAQ), GERON CORP (NASDAQ), KADMON HLDGS INC (NYSE), MERUS B V (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), KODIAK SCIENCES INC (NASDAQ), TOCAGEN INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), VERASTEM INC (NASDAQ), SAVARA INC (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), SYNLOGIC INC (NASDAQ), KAMADA (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), MANNKIND CORPORATION (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), RESTORBIO INC (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), ATHERSYS INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), IMV INC (NASDAQ), AFFIMED N V (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), COMPUGEN (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), AVITA MEDICAL LTD (ASX), RECRO PHARMA INC (NASDAQ), AXOVANT SCIENCES LTD (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), BBI LIFE SCI (HKEx), VBI VACCINES INC CDA (NASDAQ), CCMDBIO (Bursa), PIERIS PHARMACEUTICALS INC (NASDAQ), ENZO BIOCHEM INC (NYSE), ZAFGEN INC (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), ARDELYX INC (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), TREVENA INC (NASDAQ), NEON THERAPEUTICS INC (NASDAQ), STANDARD DIVERSIFIED INC (NYSE American), NABRIVA THERAPEUTICS PLC (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), COHBAR INC (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), CUE BIOPHARMA INC (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), XOMA CORP (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), PALATIN TECHNOLOGIES INC (NYSE American), PLURISTEM THERAPEUTICS INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), TELIX PHARMACEUTIC (ASX), EQUILLIUM INC (NASDAQ), CYNATA THERAPEUTICS LTD (ASX), CHAMPIONS ONCOLOGY INC (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), CHIMERIX INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), NEUREN PHARMACEUTICALS LTD (ASX), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), PFENEX INC (NYSE American), CHIASMA INC (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), NANTKWEST INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), UNI-BIO GROUP (HKEx), EDAP TMS S.A. ADS EACH REPR 1 ORD SHARE FRF0.8 (NASDAQ), SYNTHETIC BIOLOGICS INC (NYSE American), IBIO INC (NYSE American), INFINITY PHARMACEUTICALS INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), REGENT PACIFIC (HKEx), ONCOSIL MEDICAL LIMITED (ASX), ORGENESIS INC (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), IMMUTEP LTD SPON ADR EACH REP 100 ORD SHS (NASDAQ), IMMUTEP LTD (ASX), IDERA PHARMACEUTICALS INC (NASDAQ), CELLDEX THERAPEUTICS INC (NASDAQ), PORT (SET), CIDARA THERAPEUTICS INC (NASDAQ), IMMUNE DESIGN CORP (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), CT ENTERPRISE (HKEx), FORWARD PHARMA AS SPON ADR EACH REP 2 ORD SHS (NASDAQ), SESEN BIO INC (NASDAQ), INMUNE BIO INC (NASDAQ), AQUINOX PHARMACEUTICALS INC (NASDAQ), CONATUS PHARMACEUTICALS INC (NASDAQ), OTONOMY INC (NASDAQ), VERMILLION INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), OPHTHOTECH CORPORATION (NASDAQ), EVOGENE LTD (NASDAQ), PROTEON THERAPEUTICS INC (NASDAQ), NEWLINK GENETICS CORP (NASDAQ), VACCINEX INC (NASDAQ), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), ARAVIVE INC (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), PHYLOGICA LIMITED (ASX), CATABASIS PHARMACEUTICALS INC (NASDAQ), RESAPP HEALTH LIMITED (ASX), ORAGENICS INC (NYSE American), BIONOMICS LTD (ASX), VISTAGEN THERAPEUTICS INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), ASTERIAS BIOTHERAPEUTICS INC (NYSE American), IMUGENE LIMITED (ASX), ACTINIUM PHARMACEUTICALS INC (NYSE American), GENOCEA BIOSCIENCES INC (NASDAQ), ACTINOGEN MEDICAL LTD (ASX), BIONANO GENOMICS INC (NASDAQ), BIOTRON (ASX), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), MOTIF BIO PLC ADR EACH REPR 20 SHS SPON (NASDAQ), ARSANIS INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), EXTRAWELL PHAR (HKEx), CONTRAFECT CORP (NASDAQ), ONCOMED PHARMACEUTICALS INC (NASDAQ), CURIS INC (NASDAQ), SOPHIRIS BIO INC (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), AEVI GENOMIC MEDIC (NASDAQ), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), TRACON PHARMACEUTICALS INC (NASDAQ), IMMURON LIMITED (ASX), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), ADVAXIS INC (NASDAQ), BIOSINO BIO-TEC (HKEx), CEL-SCI CORP (NYSE American), NOVELION THERAPEUTICS INC (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), NANOVIRICIDES INC (NYSE American), APTOSE BIOSCIENCES INC (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), BENITEC BIOPHARMA LTD (ASX), NOVABAY PHARMACEUTICALS INC (NYSE American), CAN FITE BIOPHARMA LTD SPON ADR EA REPR 2 ORD SHS (NYSE American), SEELOS THERAPEUTICS INC (NASDAQ), GTX INC (NASDAQ), PROTEOMICS INTL LABORATORIES LTD (ASX), BENITEC BIOPHARMA LTD SPON ADR EA REPR 20 ORD (NASDAQ), VICAL INC (NASDAQ), ISORAY INC (NYSE American), SENESTECH INC (NASDAQ), KAZIA THERAPEUTICS LIMITED (ASX), ADALTA LTD (ASX), FIBROCELL SCIENCE INC (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), REGENEUS LTD (ASX), ONCONOVA THERAPEUTICS INC (NASDAQ), PATRYS LIMITED (ASX), RHINOMED LIMITED (ASX), COLLPLANT HOLDINGS LTD SPON ADR EACH REP 50 ORD(POST REV SPLT) (NASDAQ), REXAHN PHARMACEUTICALS INC (NYSE American), LIVING CELL TECHNOLOGIES (ASX), SOLIGENIX INC (NASDAQ), PRANA BIOTECHNOLOGY (ASX), CLEVELAND BIOLABS INC (NASDAQ), ANATARA LIFESCIENCES LTD (ASX), GENETIC TECHNOLOGIES (ASX), ATYR PHARMA INC (NASDAQ), ANTEO DIAGNOSTICS LIMITED (ASX), GENETIC TECHNOLOGIES SPON ADR EA REPR 150 ORD(POST SPLIT) (NASDAQ), PRANA BIOTECHNOLOGY SPON ADR EA REPR 60 ORD (POST REV SPLIT) (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), VAXART INC (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), EDGE THERAPEUTICS INC (NASDAQ), CELLMID LIMITED (ASX), AURIS MEDICAL HOLDING AG (NASDAQ), ORTHOCELL LIMITED (ASX), TROVAGENE INC (NASDAQ), OPGEN INC (NASDAQ), BIOCEPT INC (NASDAQ), CONTANGO ASSET MANAGEMENT LIMITED (ASX), BIOXYNE LIMITED (ASX), ACHIEVE LIFE SCIENCE INC (NASDAQ), ALLIQUA BIOMEDICAL INC (NASDAQ), HAO WEN HLDGS (HKEx), PRESCIENT THERAPEUTICS LIMITED (ASX), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), NEURALSTEM INC (NASDAQ), HOLISTA COLLTECH LIMITED (ASX), CYCLACEL PHARMA IN (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), VITAL THERAPIES INC (NASDAQ), MEGASUN (Bursa), CELLECTAR BIOSCIENCES INC (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), PRECIPIO INC (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), HISTOGENICS CORP (NASDAQ), NOVITA HEALTHCARE LTD (ASX), XTL BIOPHARMACEUTICALS LTD SPON ADR EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), MEMPHASYS LTD (ASX), HEMISPHERX BIOPHARMA INC (NYSE American), PHIO PHARMACEUTICALS CORP (NASDAQ), MGRC (Bursa), TBG DIAGNOSTICS LTD (ASX), MEDIBIO LIMITED (ASX), STELLAR BIOTECHNOLOGIES INC (NASDAQ), OHR PHARMACEUTICAL INC (NASDAQ), CELLECT BIOTECHNOLOGY LTD SPON ADR EACH REP 20 ORD SHS (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), PHOSPHAGENICS LTD (ASX), NANOLLOSE LTD (ASX), AMPLIA THERAPEUTICS LTD (ASX), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ), BIOBLAST PHARMA LTD (NASDAQ), MIDATECH PHARMA PLC SPON ADR EACH REP 2 ORD SHS (NASDAQ), CYTORI THERAPEUTICS INC (NASDAQ), FACTOR THERAPEUTICS LIMITED (ASX), ALCHEMIA LIMITED (ASX), CCP TECHNOLOGIES LTD (ASX), INTELLIPHARMACEUTICS INTL INC (NASDAQ), BIO-PATH HOLDINGS INC (NASDAQ), AMPLIPHI BIOSCIENCES CORPORATION (NYSE American), BPH ENERGY LIMITED (ASX), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), GENERA BIOSYSTEMS LIMITED (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+0.001
+14.29 %
10 Days -+0.001
+14.29 %
20 Days -+0.001
+14.29 %
Medium Term Return 3 Months --0.002
-20.00 %
6 Months --0.004
-33.33 %
1 Year --0.011
-57.89 %
Long Term Return 2 Years --0.056
-87.50 %
3 Years --0.107
-93.04 %
Annualised Return Annualised --
-58.87 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.006 - 0.020 Change From 1 Year Low +0.002 % Change From 1 Year Low (%) +33.33
Change From 1 Year High -0.012 % Change From 1 Year High (%) -60.00
2 Years Range 0.006 - 0.065 Change From 2 Years Low +0.002 % Change From 2 Years Low (%) +33.33
Change From 2 Years High -0.057 % Change From 2 Years High (%) -87.69
5 Years Range 0.006 - 0.560 Change From 5 Years Low +0.002 % Change From 5 Years Low (%) +33.33
Change From 5 Years High -0.552 % Change From 5 Years High (%) -98.57
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

The Group is engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of complex vascular diseases. The Group collaborates with industry specialists and physicians who are key opinion leaders to develop and offer physicians and patients new and differentiated devices to improve outcomes in complex peripheral and coronary interventions.

IPO Performance

Listing Date 29 Apr 2014 Full Subscription Rate (x) -
No of Placement Shares (M) 196.43 No of Public Offer Shares (M) - Public Offer Subscription Rate (x) -
IPO Price (SGD) 0.280 First Day Close (SGD) 0.340 First Week Close (SGD) 0.345
Current vs IPO Price (%) -97.14 First Day Gain (%) +21.43 First Week Gain (%) +23.21

Reports Download

Report Type Financial Year Ended Download
Annual Report
Annual Report 2017 Dec 2017 Part 1(0.91 MB)
Part 2(0.08 MB)
Annual Report 2016 Dec 2016 Part 1(1.60 MB)
Part 2(0.47 MB)
Annual Report 2015 Dec 2015 Part 1(0.82 MB)
Part 2(0.20 MB)
Annual Report 2014 Dec 2014 Part 1(2.05 MB)
Part 2(0.42 MB)
Annual Report 2013 Dec 2013 Part 1(1.04 MB)
IPO Prospectus
IPO Prospectus 2014 Apr 2014 Part 1(3.55 MB)

Historical Price Data

Date Open High Low Close Volume VWAP
18 Feb 2019 0.007 0.008 0.007 0.008 5,745,500 0.0073
15 Feb 2019 0.007 0.007 0.007 0.007 1,000,000 0.0070
14 Feb 2019 0.007 0.007 0.007 0.007 1,000,000 0.0070
13 Feb 2019 0.007 0.007 0.007 0.007 - -
12 Feb 2019 0.007 0.008 0.007 0.007 1,299,500 0.0075
11 Feb 2019 0.007 0.007 0.007 0.007 3,400,000 0.0070
08 Feb 2019 0.008 0.008 0.007 0.007 3,174,200 0.0070
07 Feb 2019 0.008 0.008 0.008 0.008 230,000 0.0080
04 Feb 2019 0.007 0.007 0.007 0.007 9,751,400 0.0070
01 Feb 2019 0.007 0.007 0.007 0.007 2,000,000 0.0070
31 Jan 2019 0.007 0.008 0.007 0.007 34,604,800 0.0071
30 Jan 2019 0.007 0.007 0.007 0.007 1,102,200 0.0070
29 Jan 2019 0.007 0.007 0.007 0.007 955,500 0.0070
28 Jan 2019 0.007 0.007 0.007 0.007 4,335,800 0.0070
25 Jan 2019 0.007 0.007 0.007 0.007 96,100 0.0070
24 Jan 2019 0.007 0.007 0.007 0.007 1,172,200 0.0070
23 Jan 2019 0.007 0.007 0.007 0.007 1,999,900 0.0070
22 Jan 2019 0.008 0.008 0.007 0.007 222,200 0.0079
21 Jan 2019 0.008 0.008 0.007 0.007 550,000 0.0071
18 Jan 2019 0.008 0.008 0.007 0.007 1,222,200 0.0079
17 Jan 2019 0.008 0.009 0.007 0.008 17,101,100 0.0080
16 Jan 2019 0.007 0.007 0.007 0.007 33,300 0.0070
Summary
Current 2 Weeks
(01 Feb 2019 to 18 Feb 2019)
0.007 0.008 0.007 0.008 27,600,600 -
Previous 2 Weeks
(18 Jan 2019 to 31 Jan 2019)
0.008 0.008 0.007 0.007 46,260,900 -
4 Weeks from
(19 Dec 2018 to 17 Jan 2019)
0.008 0.008 0.007 0.008 72,375,583 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.